Shots:

• Reverie Labs to receive up front and is eligible to receive pre/clinical- regulatory milestones- as well as royalties on Roche's sales of drug candidates- emerges from the collaboration
• Reverie Labs will deploy its technology platform to perform virtual screening- hit-to-lead generation- and lead optimization on kinase inhibitor discovery programs- alongside scientists at Roche and Genentech
• Reverie Labs uses its highly scalable infrastructure to train ML models for kinase potency- kinome selectivity- and ADMET properties for generating millions of novel chemical structures to evaluate the ideal combination of properties

Click here to read full press release/ article 

 Ref: PRNewswire | Image: Roche